-

Aquyre Biosciences wins top award from French American Chamber of Commerce, New England

WESTON, Mass.--(BUSINESS WIRE)--Aquyre Biosciences, Inc. the creator of CelTivity, the industry leader in two-minute lung biopsy adequacy assessment, today announced that Aquyre Biosciences and its founder Bertrand De Poly have been recognized with the 2023 FAB Life Sciences Award, from the French American Chamber of Commerce, New England.

The FAB Life Sciences Award celebrates French and American companies and entrepreneurs throughout New England that make significant and positive contributions and achievements in the field of life sciences.

“I am honored to have been nominated for this prestigious award,” said Bertrand De Poly, Founder and Chief Strategy and Technology Officer. “To receive such recognition highlights the value our technology can offer not only to proceduralists but to patients.”

Aquyre’s technology uses light to optically analyze the intracellular activity of a biopsy. This analysis takes two minutes and leaves the entire biopsy unaltered unlike current adequacy assessment techniques. The results are presented in easy-to-interpret microscopic image that allow proceduralists in-room to know if they have an adequate biopsy for final diagnosis. This past year Aquyre celebrated a major procedural milestone of over 500 biopsy analysis performed using their CelTivity system.

“We have had such quick and successful adoptions of CelTivity, for lung biopsies, in some of the top hospital systems across America, which lead us to hit an impressive procedural milestone,” said Samuel Eberts, Chief Executive Officer and Chairman of the Board. “This is a great acknowledgment of the achievements Aquyre has made in the past year.”

To learn more about Aquyre Biosciences please visit www.aquyre.com.

About Aquyre

Aquyre Biosciences, Inc is the creator of CelTivity™, the industry leader in two-minute lung biopsy adequacy assessment. Powered by two proprietary technologies including Dynamic Cell Imaging™ (DCI), CelTivity can scan a biopsy and measure intracellular and metabolic activity throughout extracted tissue. This activity is presented in a heatmap, making it easy to interpret. The assessment does not require any cutting or staining, meaning the same tissue assessed for adequacy can go to final pathology to review for cancer, granuloma, lymphocytes, and more. Aquyre Biosciences is headquartered out of Weston, Mass. For more information, please visit www.aquyre.com.

Contacts

Media
Emily Ritacco
Director of Marketing
eritacco@aquyre.com

Industry:

Aquyre Biosciences, Inc.

Release Versions
English

Contacts

Media
Emily Ritacco
Director of Marketing
eritacco@aquyre.com

More News From Aquyre Biosciences, Inc.

Aquyre Biosciences Announces Appointment of Gregory Bowles as President and CEO

WESTON, Mass.--(BUSINESS WIRE)--Aquyre Biosciences, Inc. today announced the appointment of Gregory Bowles as President, Chief Executive Officer and member of the Board of Directors. This evolution in leadership aims to take the company to the next stage with the development and launch of the Van Gogh system, an advanced phase-contrast microscope that is optimized for “specimen adequacy assessment”, a critical step in cancer diagnosis. Greg has over 20 years of experience in the medical technol...

Aquyre Biosciences Announces Appointment of F. Samuel Eberts III as CEO and Chairman of the Board of Directors & Founder Bertrand de Poly as Chief Strategy & Technology Officer

WESTON, Mass.--(BUSINESS WIRE)--Aquyre Biosciences, Inc. today announced the appointment of F. Samuel Eberts III as Chief Executive Officer and Chairman of its Board of Directors. Founder Bertrand de Poly will assume the role of Chief Strategy & Technology Officer, focusing on strategy and technological development, along with his continued service on the board. This evolution in management aims to take the company to its next stage of growth, building on recent achievements including the a...

Aquyre Biosciences Reaches Major Procedure Milestone During Lung Awareness Month

WESTON, Mass.--(BUSINESS WIRE)--Aquyre Biosciences recognizes Lung Cancer Awareness Month by reaching a milestone of over 400 lung biopsy procedures completed using the CelTivity™ microscopic system. CelTivity provides an easy-to-read image, like a PET scan for cells, making cancer cells glow. Physicians found that by using CelTivity they had a significantly higher rate of cancer detection (96%), compared to traditional methods (57%). By using CelTivity, physicians can be more confident in thei...
Back to Newsroom